Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026

Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Za

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.05 per share which beat the a

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:

Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have received an average recomm

Investors need to pay close attention to FENC stock based on the movements in the options market lat

RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:

RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Co

Fennec Pharmaceuticals NASDAQ: FENC executives outlined the company's commercial strategy for PEDMAR

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC)

~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thio

RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:F

Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript

Adherex Technologies NASDAQ: FENC executives said Fennec Pharmaceuticals entered 2026 with stronger

Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.01 per share, beating the Za

~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field S

RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:

TAIPEI, May 6, 2026 /PRNewswire/ -- Far Eastern New Century Corporation ("FENC" or "the Company") ha

Wedbush analyst David Nierengarten reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperf

~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult

~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Pa

Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has been assigned a consensus recommendat

RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ

Adherex Technologies (NASDAQ: FENC - Get Free Report) is expected to be releasing its Q4 2025 result

San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating pot

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.17) per share which missed the

Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and r

Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announ

Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announ

Piper Sandler analyst David Amsellem initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) w

Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tum

Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss

Fennec intends to use the net proceeds of the offering to repurchase and redeem certain indebtedness

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.02) per share which met the an

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a s

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC

Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Bu

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.11) per share which missed the

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC

Craig-Hallum analyst Chase Knickerbocker maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Bu

Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly losses of $(0.04) per share which beat the a

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fennec Pharmaceuticals (NASDAQ:FENC